Novo Nordisk A/S (ADR) (NYSE:NVO) plunged -0.27% or -0.15 points during previous trade after opening at the price of $54.79, a total of 2.83M shares exchanged hands compared with its average trading volume of 1.25M shares. The stock has a market capitalization of $109.76B and it has 1.96B outstanding shares.

According to consensus agreement of 1 analysts Novo Nordisk A/S (ADR) (NYSE:NVO) will report earnings per share of $0.58 in their quarterly report and it is expected to announce the company’s results on 8/5/2016 BMO. For the current quarter the company has highest EPS estimates of $0.58 and low forecast is $0.58. However a year ago for the same quarter the company has reported $0.45 earnings per share.

If we have a peek on EPS and surprise factor history during last four quarters, for the previous quarter ended on 3/2016, the consensus mean EPS was $0.53 while the company reported $0.55 EPS on 4/29/2016 BMO with a difference of 0.02 marking a surprise factor of 3.77%.

Previously for the quarter ended on 12/2015, Novo Nordisk A/S (ADR) (NYSE:NVO)’s expected mean EPS was $0.48, the company reported its quarterly earnings per share of $0.47 on 2/3/2016 BMO, missing the analysts’ consensus estimate by -0.01 with surprise factor of 2.08%.

Novo Nordisk A/S (ADR) (NYSE:NVO)’s mean EPS estimate was $0.47 for the quarter ended on 9/2015, while it reported EPS of $0.49 on 10/29/2015 BMO, beating the analysts’ consensus estimate by 0.02 with surprise factor of 4.26%.

Back on 8/6/2015 the company reported $0.48 earnings per share (EPS) for the quarter ended on 6/2015.

Average EPS forecast for the current year is $2.25 according to 2 analysts making projections for Novo Nordisk A/S (ADR) (NYSE:NVO). The most expectant earnings per share estimate of the stock is set at $2.28 while the conservative estimates kept at $2.21 over the current year. Having a look at the historical EPS report, the company attained $2.01 EPS for the previous year. While revenue estimates for the current year is 16.8B, setting the highest revenues estimates of 17.08B and indicating lowest revenues at 16.51B according to agreement of 2 number of analysts. Current revenue movements show that, the company has set average revenue estimates of 4.24B covering forecast of 1 analysts. The company indicates a peak revenue level of 4.24B and 4.24B at bottom level.

Having a glance at growth estimates of the company, it has current quarter growth estimates of 28.90% whereas for next quarter it has 18.40% estimations over growth. Its forecasts over growth are 11.90% during current year while analysts’ growth estimation for the next year is 8.90%. Past 5 years growth of Novo Nordisk A/S (ADR) (NYSE:NVO) observed at 17.99%, and for the next five years the analysts that follow this company are expecting its growth at 12.30%.

Novo Nordisk A/S (ADR) (NYSE:NVO) reached at $55.20 price level during last trade its distance from 20 days simple moving average is -0.66%, and its distance from 50 days simple moving average is 0.83% while it has a distance of 1.85% from the 200 days simple moving average. On year trading price range hit the peak level of $59.95 and touched the lowest level of $46.17 and its distance from 52 week high is -6.39% and current price is above +21.67% from 52 week low.